Theoretical Usage of Neurotoxins to Treat Neuromuscular Junction Disorders and Diseases

Adhith Theyver
West Ranch High School

Abstract

Neuromuscular Junction Diseases and Disorders pose significant challenges to those affected by them. This paper explores the therapeutic use of neurotoxins, Botulinum Neurotoxin (BoNT), and alpha-latrotoxin. We specifically look at acetylcholine and calcium ions and their interplay with neurotoxins and the neuromuscular junction. The diseases/disorders that are studied include cholinergic crisis and Lambert Eaton Myasthenic Syndrome (LEMS).

We conducted a thorough review of relevant medical and scientific literature. The information that was attained was used to support claims, draw conclusions, and establish a significant correlation between claims and data points.

Our research revealed that Botulinum Neurotoxin (BoNT) may be able to treat patients suffering from a cholinergic crisis by regulating the diffusion of neurotransmitters into the synaptic cleft. It also revealed that alpha-latrotoxin can be utilized to reactivate acetylcholinesterase, by providing an influx of calcium ions. Furthermore, it was discovered that alpha-latrotoxin can help treat patients with LEMS by lengthening the duration of a phenomenon called post-activation facilitation.

In conclusion, the evidence gathered during this research gives us theoretical means to treat neuromuscular junction diseases and disorders through the controlled application of neurotoxins.

Introduction

Neurotoxins are poisons which act on the nervous system (Walker, 2014). The nervous system is interconnected with all of the different body systems; poisons that negatively affect the nervous system end up affecting the other systems. The musculoskeletal and nervous system are connected through a series of neuromuscular junctions. Studying the effect of how neurotoxins can be used to treat neuromuscular junction disorders and diseases should be relevant for several reasons; for example, it can lead to the development of more effective treatments. The neuromuscular junction disorders explored in this study are cholinergic crisis and Lambert

Eaton Myasthenic Syndrome. Neurotoxic substances cause significant harm to those exposed to them; by better understanding the potential risks that neurotoxins pose, we can create preventative measures and appropriate treatment strategies.

The main objective of this study is to look into Botulinum Neurotoxin (BoNT), and alpha-latrotoxin and their interplay with the neuromuscular junction. BoNT is one the most poisonous biological substances known, it is a neurotoxin produced by the bacterium *Clostridium botulinum* (Nigam, 2010). BoNT has shown promise for therapeutic applications in previous studies. It is known for its paralytic effects; however, when administered in controlled doses it can target overactive muscles and provide beneficial results. Alpha-latrotoxins are a class of potent neurotoxins found within the venom of black widow spiders. We specifically look into how BoNT and alpha-latrotoxin are related to disorders like cholinergic crisis and Lambert Eaton Myasthenic Syndrome (LEMS).

The neuromuscular junction is a synaptic connection between the terminal end of a motor nerve and a muscle, where the action potential is transmitted. The transmission is carried out by neurotransmitters like acetylcholine (ACh). When a motor neuron is stimulated, an action potential releases a neurotransmitter called acetylcholine into the neuromuscular junction. Upon its release, the acetylcholine spreads across the synaptic cleft: the small gap between the axon nerve terminal and the muscle fiber (Omar, 2023). Neurotransmitters are essential for effective communication between the nervous and musculoskeletal systems.

This research paper explores various biological processes that are related to the therapeutic potential of Botulinum Neurotoxin, and alpha-latrotoxin. By examining their interactions at the neuromuscular junction we hope to usher the development of more effective treatments for neuromuscular junction diseases and disorders.

Cholinergic Crisis

A cholinergic crisis is a disorder that arises from an overstimulation of nicotinic and muscarinic receptors at neuromuscular junctions (Adeyinka, 2023). There are many causes for cholinergic crisis: an inactivation or inhibition of the acetylcholinesterase (AChE) enzyme, use of certain medications, and exposure to certain toxins. The enzyme AChE is involved with the degradation of ACh into acetyl and choline. When ACh is not degraded, it builds up, causing symptoms like cramps, salivation, lacrimation, muscular weakness, paralysis, muscular fasciculation, diarrhea, and blurry vision (Adeyinka, 2023). Neurotoxins like BoNT and alpha-latrotoxin can be used as treatment.

Botulinum Neurotoxin (BoNT) as a Treatment

Acetylcholine is released into the synaptic cleft during normal transmitter release without interference. However, when BoNT is present,

acetylcholine is prevented from being released. BoNT prevents the release of acetylcholine through its ability to cleave SNARE (SNAp REceptors) proteins. In normal transmitter release the SNARE proteins bind to synaptic vesicles which contain acetylcholine. After binding, acetylcholine is released into the synaptic cleft. However, when SNARE proteins are cleaved by BoNT, the synaptic vesicle cannot release ACh into the synaptic cleft (Nigam, 2010). During a cholinergic crisis, excessive acetylcholine is exocytosed from the axon terminal. To prevent/decelerate the rate of AcH release, BoNT can therapeutically be utilized to cleave the SNARE proteins and stop the liberation of ACh vesicles (Adeyinka, 2023).

Moderate amounts of BoNT can be used to treat cholinergic crises. BoNT has been used to treat diseases and disorders like focal dystonias, strabismus, and blepharospasm. In a study conducted by P K Ingram and Anjana Ingram, BoNT was used similarly to treat dysphagia through the cleavage of SNARE proteins (Nigam, 2010), (Alfonsi, 2017). BoNT is used as a therapeutic drug because of its profound ability to prevent the release of acetylcholine. Local injections of the neurotoxins weaken the overactive muscle and control the hypersecretion of glands. Hypersecretion of glands is a common symptom of increased ACh. In various secretory glands, ACh is shown to have excitatory effects (Bahls, 1987). Botulinum neurotoxin does not have a permanent effect on the patient; instead, it allows for nerve endings to regenerate and muscular function to reappear.

By preventing the release of acetylcholine, BoNT calms the overstimulation of the muscarinic and nicotinic receptors at the neuromuscular junction. In a situation in which AChE is deactivated, the targeting of AChE for treatment is only possible when the targeting of SNARE proteins is analogous. When SNARE proteins are cleaved and ACh release is brought closer to homeostatic levels, the body will reactivate AChE. This will give the body the necessary time to reactivate the AChE enzyme and bring the concentration of acetylcholine at the neuromuscular junction back to a homeostatic level. If no medication or treatment is used, the body will keep on releasing ACh which will lead to even more dire consequences: permanent muscle damage or dysfunction.

Alpha-latrotoxin as a Treatment

A complex therapeutic approach is the usage of alpha-latrotoxin to treat cholinergic crises through the release of calcium ions. Alpha-latrotoxin has evolved to induce a massive release of neurotransmitters (ACh) from presynaptic nerve terminals (Henkel, 1999). This uncontrolled release can initially exacerbate the cholinergic crisis; however, it will end up triggering a cascade of biological events that can alleviate the cholinergic crisis.

Alpha-latrotoxin can only be used as a possible treatment for cholinergic crises that are caused by the inhibition of acetylcholinesterase.

When alpha-latrotoxin is introduced to the neuromuscular junction, it binds to specific receptors on the presynaptic nerve terminals and causes a rush of acetylcholine into the synaptic cleft (Henkel, 1999). Even though adding more acetylcholine to a state of cholinergic crisis may seem counterintuitive, it is crucial to the next event in the pathway. An increased concentration of ACh leads to further binding with ligand-gated nicotinic acetylcholine receptors: ACh is the ligand. The binding causes the channel to open, resulting in sodium ions flowing into the cell. After the depolarization reaches a certain threshold, voltage-gated calcium ion channels (VGCC) open (Unwin, 2013). Similarly, the binding of ACh to the G-protein coupled muscarinic acetylcholine receptors leads to the modulation of a pathway that can activate VGCC (Haga, 2013). An activated/open VGCC leads to an influx of calcium ions.

Calcium ions are not necessarily cofactors of acetylcholinesterase, but they have been shown to increase the reaction rate of the enzyme (Trang, 2023). Calcium ions can stabilize the molecular structure of acetylcholinesterase. The enzyme has an anionic site, the positively charged calcium ions will bind to the negatively charged amino acids that line the anionic site. An anionic site is one that is similar to an active site and its state of binding can affect the activity of the enzyme. As calcium is a benefactor for AChE, it will increase the enzymatic activity for acetylcholinesterase and will terminate the cholinergic crisis signal.

Utilizing alpha-latrotoxin presents a complex yet promising therapeutic approach. It should be noted that its use should only be applied when a cholinergic crisis arises because of acetylcholinesterase inhibition.

Neurotoxin Treatment for Cholinergic Crisis: Considerations, Benefits, and Risks

There are various benefits and risks for neurotoxin treatment for patients diagnosed with cholinergic crisis.

Normal medication and BoNT work in the same manner to treat cholinergic crisis: the prevention of acetylcholine release. Alpha-latrotoxin works like a medication called Pralidoxime, which treats cholinergic crises through the reactivation of acetylcholinesterase. Even though the method of reactivation is different, the principle remains the same (Gupta). The application of the neurotoxin as a treatment should be controlled and done by a professional. Many factors should be taken into account before BoNT is used clinically. It is highly potent, and if used improperly it can lead to severe neurological and muscular damage. There should be a precise injection technique, and the treatment should be contained in the area that is affected by the cholinergic crisis (Alfonsi, 2017). Also, not all patients will be suitable for neurotoxin treatment. For example, neurotoxins can interfere with other medications, so it is essential to identify other medications during patient evaluation.

Even though there are serious considerations and risks, there are also many benefits. The application of neurotoxins shows promise for

targeted treatment, which is a stark contrast to conventional treatment. During conventional treatment, both healthy and affected cells come in contact with treatment, which can lead to unpleasant side effects. However, with targeted treatment, the amount of healthy cells exposed to treatment is limited, therefore limiting the potency of the side effects. Also, it can allow for a more personalized care route for the patient. It is easier for healthcare professionals to prevent the under and over-dosage of neurotoxins when compared to traditional drugs. Neurotoxins like BoNT work quickly, so after they are injected they allow for rapid release. Rapid release constitutes rapid relief for the patient.

Lambert-Eaton Myasthenic Syndrome

Lambert-Eaton Myasthenic Syndrome (LEMS), is a rare autoimmune disorder that affects the neuromuscular junction. When LEMS is present, autoantibodies go against voltage-gated calcium channels (VGCC). VGCCs play a crucial role in transmitting nerve signals to the muscles. VGCC regulates the influx and concentration of calcium ions; they diminish the release of ACh into the synaptic cleft. Reduction of ACh results in inefficient transmission of nerve signals to the muscle (Jayarangaiah, 2023).

Post-activation facilitation is something very unique about LEMS. At the beginning of the autoimmune attack, VGCCs are not functioning within their optimal range, leading to a reduction in the release of neurotransmitters. (Jayarangaiah, 2023), (Heck, 2021). Neurotransmitters move per the electrochemical gradient, which is altered and controlled by the movement of calcium ions. When calcium channels are damaged, the neuromuscular junction experiences weaker nerve stimulation. Post-activation facilitation is characterized by the repeated stimulation of weak nerve signals; this repeated stimulation causes the build of calcium ions in the nerve terminals. Built-up calcium ions directly accelerate the movement of the neurotransmitters, because of the electrochemical gradient. The final result of this process is improved muscular function and stronger muscle contractions with each excessive stimulation. In theory, if this state of improved muscular function is maintained, then treatment and overall patient well-being would improve drastically.

Alpha-latrotoxin as a Treatment

Alpha-latrotoxin is a neurotoxin that is known for increasing the concentration of calcium ions in the neuromuscular space [8]. It does this by depolarizing the nerve terminals and causing an influx of calcium ions. Voltage-gated calcium channels are impaired, but a reduced amount of calcium ions can still pass through. Even if there is limited transmission of calcium ions, post-activation facilitation can still occur. In theory, if post-activation facilitation was prolonged, then treatment would be more simplified and more accurate. Post-activation facilitation involves an increase in nerve impulses, which extends the duration of facilitation.

Calcium ions can still pass through damaged/impaired VGCC for a variety of reasons [7]. The VGCC will still be able to retain partial functionality, meaning that it will be able to depolarize to some extent. The damaged VGCC may always have had a changed threshold for activation. This means that the damage to the calcium channel would only slightly affect the rate of calcium ion transmission. Alpha-latrotoxin depolarizes the nerve terminal causing an influx of calcium ions. Alpha-latrotoxin binds to specific receptors on the presynaptic membrane of nerve cells. Once they are bound to their respective receptor proteins, alpha-latrotoxin induces a conformational change in the receptor protein, leading to the formation of ion channels. During post-activation facilitation, the threshold for activation of muscle fibers is reduced [4]. This reduction means that a lower concentration of calcium ions will result in the activation of the muscle fiber, making the damaged VGCC more viable as it releases fewer calcium ions.

These newly formed channels allow an influx of calcium ions into the nerve terminal. This newly discovered concentration will accelerate the movement of neurotransmitters like acetylcholine. Calcium ions will bind to specific proteins in the nerve terminal called synaptic vesicle proteins. This binding triggers the fusion of synaptic vesicles with the presynaptic membrane, which then releases the contents into the synaptic cleft. The released acetylcholine binds to acetylcholine receptors on the cell membranes, causing the activation of the muscle fiber. This activated muscle fiber will increase the overall function of the muscles that are deprived of stimulation. When multiple contractions come together, the overall effect on the body is positive. Therefore, the calcium ions released from alpha-latrotoxin cause an increase in acetylcholine, leading to a prolonged phase of post-activation facilitation.

The duration of post-activation facilitation relies on many factors. One of them is the strength of the initial reaction. The initial reaction is characterized by the muscles' response to the first stimulus. It is triggered by the influx of calcium ions, which leads to a more intense and longer initial activation. This is so because the influx has a stronger concentration in comparison to homeostatic levels. This will lead to a more pronounced post-activation facilitation. Another important factor is the frequency of stimulation; when muscle fibers are stimulated repetitively [7]. This then leads to the accumulation of calcium ions. The calcium ions lead to an extended duration of post-activation facilitation. Not only does alpha-latrotoxin help usher in post-activation facilitation, but it also helps maintain it. This task is completed because of a variety of factors, one being the availability of calcium ions.

In a research paper by Michal Keogh, Saam Sedehizadeh, and Paul Maddison, 3,4 Diaminopyridine was used to treat LEMS in patients with varying situations; 3,4 Diaminopyridine resulted in an overall positive effect on the people it was administered to. It also helps the restoration of calcium ion influx. It does this by blocking some potassium channels on

nerve terminals. These channels tend to prevent the influx of calcium ions. When potassium channels are blocked, calcium ions can enter the nerve terminals easily. When calcium ions enter, they are accompanied by an influx of acetylcholine. Most patients were reported to have restoration of neuromuscular function and improved muscle strength [10].

The outcomes in the patients indicated the presence/forthcoming of post-activation facilitation. Even though it was not explicitly stated in the project; it can be assumed it did occur. A common sign of post-activation facilitations is the return of muscle strength with repeated muscle contraction. In the study, muscle strength was regained and measured through myometry. After the 3,4 Diaminopyridine was applied, CMAP (Compound Muscle Action Potential) was measured. The results showed a general increase in CMAP levels in the patients. CMAP is an electrical measure of the summated action potentials of all stimulated motor endplates, it reflects increased muscle contractions [10][14]. The elevated CMAP levels could also indicate the existence of post-activation facilitation; a higher CMAP level indicates increased muscle contraction. If there are increased muscle contractions during LEMS; post-activation facilitation alleviates the symptoms and overall wellness of the patient. In conclusion 3,4 Diaminopyridine acts similarly to alpha-latrotoxin, inducing post-activation facilitation.

Neurotoxin Treatment for Lambert Eaton Myasthenic Syndrome: Considerations, Benefits, and Risks

If alpha-latrotoxin is used in incorrect proportions, then the increased concentration of calcium ions and acetylcholine will end up hurting the body. Examples of adverse health effects are muscle cramps, nervous system overstimulation, cardiovascular effects, overall weakness, and systemic toxicity [8]. If alpha-latrotoxin is used improperly, then the outcome may be worse than the original state of LEMS.

However, several precautions and considerations can be taken to ensure the veracity of alpha-latrotoxin as a treatment. One is precise dosage, even the slightest deviation from the appropriate amount can lead to serious health implications. Another precaution is appropriate localization: alpha-latrotoxin should be aimed at specific nerve channels and neuromuscular junctions. If patients undergo this treatment they should be under constant monitoring by the medical staff: extreme side effects are possible. Using alpha-latrotoxin as a treatment is just a theoretical idea, and must undergo further study before it is ready for real-world application.

Even though there is an abundance of precautions, there are some benefits. Alpha-latrotoxin treatment would be minimally invasive, and would only require an injection. The neurotoxin doses will be dependent on the patient's unique circumstances, allowing for a tailored approach.

Conclusion

Cholinergic crisis and LEMS present intriguing theoretical treatments that involve the application of neurotoxins like botulinum neurotoxin and alpha-latrotoxin. They both have therapeutic potential through the regulation of neurotransmitters. BoNT has therapeutic potential through the regulation of neurotransmitters, whereas alpha-latrotoxin can provide treatment by increasing the calcium ion concentration at the neuromuscular junction.

In cholinergic crisis, BoNT has shown promise in preventing overstimulation of muscarinic and nicotinic receptors. BoNT has been shown as a treatment for disorders like dysphagia [2]. Alpha-latrotoxin helps reactive acetylcholinesterase by increasing the concentration of calcium ions [8]. The calcium ions will help reactivate the deactivated enzymes, as calcium ions are benefactors of acetylcholinesterase. Reactivated AChE will bring down the concentration of acetylcholine to homeostatic levels.

For Lambert Eaton Myasthenic Syndrome (LEMS), alpha-latrotoxin brings forth post-activation facilitation. It does this by causing stronger muscle activations; stronger muscle palpitations help usher in post-activation facilitation and help maintain a state of it. An extended post-activation facilitation will result in long-term benefits for individuals suffering from LEMS.

In summary, neurotoxins like botulinum neurotoxin and alpha-latrotoxin show promise in the treatment of neuromuscular junction diseases and disorders. By targeting specific aspects of the neurotransmitter release process, these therapies offer hope for improved management and outcomes for patients suffering from conditions like cholinergic crisis and LEMS. It must be noted that further research and trials are necessary to harness the full potential of this type of treatment.

References

Adeyinka, A. (2023, August 12). Cholinergic crisis. *StatPearls [Internet]*. https://www.ncbi.nlm.nih.gov/books/NBK482433/

Alfonsi, E., Restivo, D. A., Cosentino, G., De Icco, R., Bertino, G., Schindler, A., Todisco, M., Fresia, M., Cortese, A., Prunetti, P., Ramusino, M. C., Moglia, A., Sandrini, G., & Tassorelli, C. (2017). Botulinum toxin is effective in the management of neurogenic dysphagia. Clinical-electrophysiological findings and tips on safety in different neurological disorders. *Frontiers in Pharmacology, 8,* 80. https://doi.org/10.3389/fphar.2017.00080

Bahls, F. (1987). Acetylcholine-induced responses in the salivary gland cells of Helisoma trivolvis. *Cellular and Molecular Neurobiology, 7*(1), 35–47. https://doi.org/10.1007/BF00734988

Blazevich, A. J., & Babault, N. (2019). Post-activation potentiation versus post-activation performance enhancement in humans: Historical perspective, underlying mechanisms, and current issues. *Frontiers in Physiology, 10,* 1359. https://doi.org/10.3389/fphys.2019.01359

Gupta, R. Pralidoxime. *StatPearls [Internet]*. https://www.ncbi.nlm.nih.gov/books/NBK558908/

Haga, T. (2013). Molecular properties of muscarinic acetylcholine receptors. *Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 89*(6), 226–256. https://doi.org/10.2183/pjab.89.226

Heck, J., Palmeira Do Amaral, A. C., Weißbach, S., El Khallouqi, A., Bikbaev, A., & Heine, M. (2021). More than a pore: How voltage-gated calcium channels act on different levels of neuronal communication regulation. *Channels (Austin, Tex.), 15*(1), 322–338. https://doi.org/10.1080/19336950.2021.1900024

Henkel, A. W., & Sankaranarayanan, S. (1999). Mechanisms of alpha-latrotoxin action. *Cell and Tissue Research, 296*(2), 229–233. https://doi.org/10.1007/s004410051284

Jayarangaiah, A. (2023, October 23). Lambert-Eaton myasthenic syndrome. *StatPearls [Internet]*. https://www.ncbi.nlm.nih.gov/books/NBK507891/

Keogh, M., Sedehizadeh, S., & Maddison, P. (2011). Treatment for Lambert-Eaton myasthenic syndrome. *The Cochrane Database of Systematic Reviews, 2011*(2), CD003279. https://doi.org/10.1002/14651858.CD003279.pub3

Lorenz, D. (2011). Postactivation potentiation: An introduction. *International Journal of Sports Physical Therapy, 6*(3), 234–240.